Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177814 · ClinicalTrials.gov registry record
Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit
A clinical trial of Gram-negative Bacterial Infections, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT00177814: Completed study of Gram-negative Bacterial Infections, sponsored by University of Pittsburgh.
NCT00177814 is a study of Gram-negative Bacterial Infections that has completed, run by University of Pittsburgh. The registered enrollment target is 1,000 participants, above the 192-participant average among 4 other Gram-negative Bacterial Infections trials with a reported enrollment target (421% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177814, a study of Gram-negative Bacterial Infections, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) \[measured as defined daily doses per 1000 patient days\]; physician acceptance of piperacillin as part of a streamlining program \[measured as successful occurrences of the use of piperacillin as streamlining therapy\]; changes in susceptibility patterns of broad spectrum antibiotics \[measured as % Gram negative bacilli susceptible to each of the commonly used broad spectrum antibiotics\]; and outcome of patients treated with streamlined therapy.
Primary Outcome
health status
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2005-09 |
| Est. Completion | 2017-06 |
What the finished NCT00177814 record still lists
NCT00177814 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 192-participant average among 4 other Gram-negative Bacterial Infections trials with a reported enrollment target (421% higher).
The record links to 1 condition, with Gram-negative Bacterial Infections appearing as the primary indexed condition, and to 0 interventions.
NCT00177814 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00177814 about?
NCT00177814 is a clinical study titled "Piperacillin as a Part of Antibiotic Streamlining in the Intensive Care Unit". The proposed endpoints of the study would be: comparative use of piperacillin versus broader spectrum agents (e.g., piperacillin/tazobactam, etc.) \[measured as defined daily doses per 1000 patient days\]; physician acceptance of piperacillin as part of a streamlining program \[measured as successfu...
What is the current status of trial NCT00177814?
This trial is currently completed. The enrollment target is 1,000 participants. The study started on 2005-09. Estimated completion is 2017-06.
What conditions does trial NCT00177814 study?
This clinical trial studies the following conditions: Gram-negative Bacterial Infections.
Who is sponsoring clinical trial NCT00177814?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00177814 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gram-negative Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
RECRUITING · Phase 2
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
COMPLETED · Phase 2
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
COMPLETED · Phase 2
-
Gram Negative Bacteremia, Risk Factors for Failure of Therapy
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia